India to Bangladesh: Rituximab Export Trade Route

The India to Bangladesh Rituximab corridor is one of India's established pharmaceutical export routes, with 6 shipments documented worth a combined $271.1K USD. The route is dominated by DR.REDDY'S LABORATORIES LTD, which alone accounts for roughly 59% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.

Across 3 active suppliers, the average shipment value stands at $45.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 77% of all shipments, consistent with rituximab's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 17 days port-to-port. The route has recorded an annual growth rate of 20.3%, placing it at rank #16 among India's top rituximab export destinations globally.

On the import side, key buyers of Indian rituximab in Bangladesh include HEALTHCARE PHARMACEUTICALS LTD.,, XXVANXXD CXXMICXX INXXSTRXXS LXX, XXCEPXX PHXXMACXXTICXXS LXXITEX and 2 others. HEALTHCARE PHARMACEUTICALS LTD., is the single largest importer with 2 shipments valued at $160.7K USD.

India's rituximab exports to Bangladesh are driven primarily by a handful of large-scale manufacturers. DR.REDDY'S LABORATORIES LTD with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 3 active exporters signals a competitive but concentrated market — buyers in Bangladesh benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, HETERO BIOPHARMA LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $45.2K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as rituximab (10mg/ml)( export) and rituximab (10 mg/ml)(export), suggesting that buyers in Bangladesh tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, HEALTHCARE PHARMACEUTICALS LTD., is the largest importer with 2 shipments worth $160.7K USD — representing 59% of all rituximab imports from India on this route.